Cytokinetics prices $700M upsized public offering of common stock

Cytokinetics announced the pricing of an upsized public offering of 9.86 million shares at $71 each, aiming to raise about $700 million before expenses. The offering is expected to close on May 8, 2026, and includes an option for underwriters to buy an additional 1.48 million shares. Proceeds will support Cytokinetics' development of cardiovascular drugs, including its approved MYQORZO® and investigational treatments for heart failure. This capital raise strengthens the company's financial position to advance its pipeline.